Lantheus Holdings Inc. (LNTH) Shares Down 10.8%
Lantheus Holdings Inc. (NASDAQ:LNTH) shares were down 10.8% on Monday . The stock traded as low as $5.21 and last traded at $5.35, with a volume of 395,725 shares changing hands. The stock had previously closed at $6.00.
A number of research firms have recently commented on LNTH. Zacks Investment Research upgraded Lantheus Holdings from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Friday, May 6th. Jefferies Group reaffirmed a “buy” rating on shares of Lantheus Holdings in a research note on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 price target on Lantheus Holdings and gave the stock a “hold” rating in a research note on Friday, August 5th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Lantheus Holdings currently has an average rating of “Buy” and an average target price of $5.80.
The stock has a 50 day moving average price of $4.31 and a 200 day moving average price of $2.67. The stock has a market cap of $176.24 million and a PE ratio of 6.55.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.18. The company had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. On average, equities research analysts predict that Lantheus Holdings Inc. will post $0.48 EPS for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.